All Product News

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dicloxacillin Sodium Capsules USP, 250mg and 500mg. Aurobindo Pharma’s Dicloxacillin Sodium Capsules are an AB-rated generic equivalent to the reference listed drug (RLD), Pathocil® Capsules, manufactured by Wyeth Ayerst Laboratories. Dicloxacillin Sodium […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Exemestane Tablets USP, 25 mg.  Aurobindo Pharma’s Exemestane Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), AROMASIN® tablets, manufactured by Pfizer Inc, USA.   Exemestane Tablets are indicated for: […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Vigabatrin Tablets USP, 500 mg.  Aurobindo Pharma’s Vigabatrin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), SABRIL® tablets, manufactured by Lundbeck Pharmaceuticals LLC.  Vigabatrin Tablets are indicated for: Adjunctive […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Acyclovir Oral Suspension USP, 200 mg/5 mL. Aurobindo Pharma’s Acyclovir Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ZOVIRAX ® (acyclovir), of Mylan Pharmaceuticals Inc. Acyclovir Oral Suspension […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bromfenac Ophthalmic Solution 0.09%. Aurobindo Pharma’s Bromfenac Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), Bromday™ Ophthalmic Solution, of Bausch & Lomb. Bromfenac Ophthalmic Solution are indicated for: Postoperative inflammation and reduction of […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clobazam Oral Suspension, 2.5mg/mL. Aurobindo Pharma’s Clobazam Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ONFI® Oral Suspension, of Lundbeck Pharmaceuticals LLC . Clobazam Oral Suspension  are […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Colchicine Tablets USP, 0.6 mg. Aurobindo Pharma’s Colchicine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), COLCRYS® Tablets, of Takeda Pharmaceuticals USA, Inc. Colchicine Tablets are indicated in: […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg . Aurobindo Pharma’s Nebivolol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Bystolic® Tablets, of Allergan Sales, LLC. Nebivolol Tablets are […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Prednisone Tablets USP, 1mg. Aurobindo Pharma’s Prednisone Tablets USP, 1mg, are an AB-rated generic equivalent to the reference listed drug (RLD), Meticorten® Tablets, of Schering Corp Sub Schering Plough Corp. Prednisone Tablets are […]

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Vigabatrin for Oral Solution USP, 500 mg . Aurobindo Pharma’s Vigabatrin for Oral Solution USP, 500 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Sabril for Oral Solution of […]

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Fenofibrate Capsules USP, 67mg, 134mg, and 200mg. Aurobindo Pharma’s Fenofibrate Capsules USP, 67mg, 134mg, and 200mg are an AB-rated generic equivalent to the reference listed drug (RLD), Tricor Capsules of AbbVie, Inc. Fenofibrate […]

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg. Aurobindo Pharma’s Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg are an AB-rated generic equivalent to the reference listed drug (RLD), Namenda XR […]